Level A· Stronger Clinical EvidenceMeta-analysisEurope PMCOpen access

Efficacy of a single intra-articular injection of mesenchymal stem cells for knee osteoarthritis: a dose-focused meta-analysis of randomized controlled trials

Rahmadian R., Ariliusra Z., Kusuma KRA., Ali H., Raymond B., Meksiko R.

Meta-analysis with a reported sample of 300 on Knee Osteoarthritis, Osteoarthritis, published in J Orthop Surg Res (2025) — summary generated from the PubMed abstract.

Open my reading list
Level A· Stronger Clinical EvidenceEvidence level of this study

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Meta-analysis
Journal
J Orthop Surg Res (2025)
Reported sample size
300
Source database
Europe PMC
PMID
40886001
PMCID
PMC12398016
DOI
10.1186/s13018-025-06190-4

Abstract (original English)

Background Intra-articular injection of mesenchymal stem cells (MSCs) has emerged as a promising therapy for knee osteoarthritis (OA). However, uncertainty remains regarding the optimal cell dose for maximizing clinical benefit. This systematic review and meta-analysis aimed to evaluate the efficacy of MSC injections for knee OA and investigate the relationship between cell dose and treatment outcome. Methods A comprehensive literature search was conducted in PubMed and Scopus for randomized controlled trials (RCTs) published between 2015 and 2025. Eligible studies were RCTs that used intra-articular MSC injections for knee OA, and WOMAC scores were reported at baseline and 12-month follow-up. Standardized mean differences (SMDs) were pooled using a random-effects model. Subgroup analysis and meta-regression were performed to evaluate the effect of MSC dose on treatment outcomes. Results Eight treatment arms from six RCTs involving 300 patients were included. The pooled SMD in the WOMAC score at 12 months was -1.35 (95% CI: -1.97 to -0.74), indicating a moderate to large treatment effect. MSC doses of ≤ 25 million cells were associated with statistically significant improvement, while higher doses did not demonstrate additional benefit. Meta-regression confirmed no significant dose-response relationship. Heterogeneity was moderate (I2 = 49.8%). Conclusion Intra-articular MSC th

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
HumansOsteoarthritis, KneeTreatment OutcomeMesenchymal Stem Cell TransplantationInjections, Intra-ArticularRandomized Controlled Trials as Topic

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research